Alison Crawford
Director, Immuno?Oncology Regeneron Pharmaceuticals
Seminars
Wednesday 24th June 2026
Panel Discussion: Reflecting on Past Successes & Future Challenges Across the T-Cell Engager Landscape to Assess the Benchmark for Success & Accelerate TCEs to Patients
8:30 am
- Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
- Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
- Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies
Wednesday 24th June 2026
Advancing Immuno‑Oncology Breakthroughs & Reducing Toxicity Risks Through Next‑Generation Preclinical Models
11:30 am
- Gaining insights using cutting‑edge preclinical models to model toxicity mitigation strategies and on‑target/off‑tumor effects
- Understanding optimized dosing strategies can expand therapeutic windows and improve the safety profile of next‑generation immunotherapies
